Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer. According to the FDA label for Lurbinectedin, the recommended dose is 3.2 mg/m2 administered as an intravenous infusion over 60 minutes every 21 days [2]. The maximum daily dose of Lurbinectedin is not explicitly stated in the sources provided. However, the recommended dose should not be exceeded without the advice of a healthcare professional [2]. Additionally, the FDA label provides dosing guidelines based on the patient's body surface area, which should be calculated by a healthcare professional [2]. The Medscape reference also provides the same dosing information as the FDA label [3]. The Drug Patent Watch website provides information about the patent and exclusivity status of Lurbinectedin but does not provide information about the maximum daily dose [1]. It is important to note that the maximum daily dose of Lurbinectedin may vary depending on the patient's individual characteristics and medical history, and should be determined by a healthcare professional.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] FDA. Zepzelca (lurbinectedin) injection, for intravenous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] Medscape. Lurbinectedin (Zepzelca). Retrieved from https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075